ETF Holdings Breakdown of EXAS

Stock Name	EXACT Sciences Corporation
Ticker	EXAS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US30063P1057
LEI	549300VM3X1FYD4N9Z14

News associated with EXAS

XBI, EXAS, ALNY, NTRA: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $288.7 million dollar outflow -- that's a 5.9% decrease week over week - 2025-05-09 14:52:51
Exact Sciences (NASDAQ:EXAS) Stock Price Up 3.6% Following Analyst Upgrade: Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) was up 3.6% on Monday after Barclays raised their price target on the stock from $55.00 to $75.00. Barclays currently has an overweight rating on the stock. Exact Sciences traded as high as $53.87 and last traded at $53.43. Approximately 587,969 shares changed hands during mid-day trading, […] - 2025-05-06 05:10:58
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by NewEdge Advisors LLC: NewEdge Advisors LLC lessened its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 66.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,989 shares of the medical research company’s stock after selling 7,911 shares during the quarter. NewEdge […] - 2025-05-02 08:19:03
Guggenheim Capital LLC Decreases Stock Position in Exact Sciences Co. (NASDAQ:EXAS): Guggenheim Capital LLC reduced its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 28,797 shares of the medical research company’s stock after selling 4,459 shares during the period. Guggenheim Capital LLC’s holdings in Exact Sciences were worth $1,618,000 at the end […] - 2025-04-21 08:14:52
Brokerages Set Exact Sciences Co. (NASDAQ:EXAS) Price Target at $69.25: Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twenty-two analysts that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong […] - 2025-04-21 05:46:53
Cerity Partners LLC Boosts Stake in Exact Sciences Co. (NASDAQ:EXAS): Cerity Partners LLC lifted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 65.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 27,090 shares of the medical research company’s stock after acquiring an additional 10,761 shares during the period. Cerity Partners LLC’s holdings […] - 2025-04-18 08:00:55
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Alliancebernstein L.P.: Alliancebernstein L.P. lowered its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 92.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 69,845 shares of the medical research company’s stock after selling 890,747 shares during the quarter. Alliancebernstein L.P.’s holdings in Exact […] - 2025-04-15 07:50:49
CIBC Private Wealth Group LLC Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS): CIBC Private Wealth Group LLC lowered its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 11.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,357 shares of the medical research company’s stock after selling 426 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Exact Sciences were worth $190,000 at […] - 2025-04-07 08:04:59
Mitsubishi UFJ Trust & Banking Corp Has $4.50 Million Stake in Exact Sciences Co. (NASDAQ:EXAS): Mitsubishi UFJ Trust & Banking Corp cut its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 80,058 shares of the medical research company’s stock after selling […] - 2025-03-31 08:40:55
Corient Private Wealth LLC Sells 13,018 Shares of Exact Sciences Co. (NASDAQ:EXAS): Corient Private Wealth LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 40.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,813 shares of the medical research company’s stock after selling 13,018 shares during the period. […] - 2025-03-27 08:42:59
Intech Investment Management LLC Trims Position in Exact Sciences Co. (NASDAQ:EXAS): Intech Investment Management LLC reduced its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 70.3% during the 4th quarter, Holdings Channel reports. The fund owned 3,560 shares of the medical research company’s stock after selling 8,426 shares during the period. Intech Investment Management LLC’s holdings in Exact Sciences were worth $200,000 as of […] - 2025-03-27 08:03:08
Exact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of “Moderate Buy” from Brokerages: Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1-year […] - 2025-03-24 06:08:55
M&T Bank Corp Sells 1,293 Shares of Exact Sciences Co. (NASDAQ:EXAS): M&T Bank Corp lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,963 shares of the medical research company’s stock after selling 1,293 shares during the period. M&T Bank […] - 2025-03-14 08:08:55
SBI Securities Co. Ltd. Makes New Investment in Exact Sciences Co. (NASDAQ:EXAS): SBI Securities Co. Ltd. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,183 shares of the medical research company’s stock, valued at approximately $66,000. A number of other large investors […] - 2025-03-10 07:46:54
Proficio Capital Partners LLC Makes New Investment in Exact Sciences Co. (NASDAQ:EXAS): Proficio Capital Partners LLC purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 28,545 shares of the medical research company’s stock, valued at approximately $1,604,000. A number of other institutional investors and hedge funds have […] - 2025-03-07 09:26:49
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Private Advisor Group LLC: Private Advisor Group LLC lowered its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 9.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,796 shares of the medical research company’s stock after selling 2,253 shares during the quarter. Private Advisor Group […] - 2025-02-28 09:15:01
First Horizon Advisors Inc. Sells 502 Shares of Exact Sciences Co. (NASDAQ:EXAS): First Horizon Advisors Inc. decreased its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 20.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,970 shares of the medical research company’s stock after selling 502 shares during the period. First Horizon Advisors Inc.’s holdings in Exact Sciences were worth $111,000 as of its […] - 2025-02-27 09:05:00
Exact Sciences (NASDAQ:EXAS) Trading Up 4.8% on Analyst Upgrade: Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) shares traded up 4.8% during mid-day trading on Monday after Scotiabank raised their price target on the stock from $70.00 to $73.00. Scotiabank currently has a sector outperform rating on the stock. Exact Sciences traded as high as $51.50 and last traded at $51.64. 762,199 shares changed […] - 2025-02-25 06:04:51
CIBC Asset Management Inc Has $416,000 Holdings in Exact Sciences Co. (NASDAQ:EXAS): CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,396 shares of the medical research company’s stock after acquiring an additional 907 shares […] - 2025-02-24 10:06:54
Rhumbline Advisers Sells 5,997 Shares of Exact Sciences Co. (NASDAQ:EXAS): Rhumbline Advisers lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 217,428 shares of the medical research company’s stock after selling 5,997 shares during the quarter. Rhumbline Advisers’ holdings in Exact Sciences were worth $12,217,000 as of its […] - 2025-02-24 09:04:55
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Principal Financial Group Inc.: Principal Financial Group Inc. cut its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 22.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 808,515 shares of the medical research company’s stock after selling 240,741 shares during the period. Principal Financial Group Inc. owned 0.44% […] - 2025-02-21 09:49:09
Van ECK Associates Corp Sells 13,023 Shares of Exact Sciences Co. (NASDAQ:EXAS): Van ECK Associates Corp trimmed its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,842 shares of the medical research company’s stock after selling 13,023 shares during the […] - 2025-02-18 08:36:53
Brokerages Set Exact Sciences Co. (NASDAQ:EXAS) Target Price at $72.76: Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given an average rating of “Moderate Buy” by the nineteen research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average 1 year price […] - 2025-02-05 06:38:52
Exchange Traded Concepts LLC Sells 843 Shares of Exact Sciences Co. (NASDAQ:EXAS): Exchange Traded Concepts LLC reduced its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 6.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,669 shares of the medical research company’s stock after selling 843 shares during the period. Exchange Traded Concepts LLC’s holdings in […] - 2025-01-30 08:53:03

EXAS institutional holdings

The following institutional investment holdings of EXAS have been identified

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc))	233,204	USD 12,373,804 -0.4%
2025-05-08	IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist))	233,204	USD 12,373,804
2025-05-08	IE00BKBF6H24 (iShares Core MSCI World UCITS ETF)	233,204	USD 12,373,804
2025-05-08	IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist))	233,204	USD 12,373,804
2025-05-08	IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist))	43,749 -0.3%	USD 2,321,322 -0.7%
2025-05-08	IE00B6R52259 (iShares MSCI ACWI UCITS ETF)	39,355	USD 2,088,176
2025-05-08	IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc))	48,544	USD 2,575,745
2025-05-08	IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist))	48,544	USD 2,575,745
2025-05-08	IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc))	48,544 0.0%	USD 2,575,745 -0.4%
2025-05-08	IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist))	16,615	USD 881,592 -0.4%
2025-05-08	IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP)	3,538	USD 187,726 -0.4%
2025-05-08	IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP)	3,538	USD 187,726
2025-05-08	IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist))	17,030	USD 903,612
2025-05-08	IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF)	17,030 -0.4%	USD 903,612 -0.9%
2025-05-08	IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc))	10,495	USD 493,784
2025-05-08	IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc))	6,081	USD 322,658 -0.4%
2025-05-08	IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD)	4,654	USD 246,941
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	234,759	USD 12,456,313
2025-05-08	IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF)	4,295	USD 227,893 -0.4%
2025-05-08	IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc))	4,295	USD 227,893 -0.4%
2025-05-08	IE00BN92ZL31 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist))	960	USD 50,938 -0.4%
2025-05-08	IE00BMXC7W70 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Acc))	960	USD 50,938 -0.4%
2025-05-08	IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc))	1,000	USD 39,866
2025-05-08	IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc))	7,200	USD 382,032
2025-05-08	IE00BD1F4K20 (iShares MSCI USA Mid-Cap Equal Weight UCITS ETF USD (Acc))	19,891	USD 1,055,416 -0.4%
2025-05-08	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	862	USD 45,738 -0.4%
2025-05-08	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	786	USD 41,705
2025-05-08	IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc))	39,355	USD 2,088,176
2024-11-08	IE000X08RX14 (iShares MSCI World ESG Enhanced UCITS ETF NZD Hedged (Acc))	3,237	USD 166,641 -3.4%
Total =	1,558,133	USD 82,593,149

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.